(Q40840477)

24 September 2017

1 reference

title

Future of lipid-lowering trials: what else do we need to know? (English)

1 reference

24 September 2017

P H Jones

1

1 reference

24 September 2017

language of work or name

English

0 references

publication date

1 September 1998

1 reference

American Journal of Cardiology

24 September 2017

published in

1 reference

24 September 2017

volume

82

1 reference

24 September 2017

issue

6A

1 reference

24 September 2017

page(s)

32M-38M

1 reference

Shattuck lecture--cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities

24 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900595-5

Declining serum total cholesterol levels among US adults. The National Health and Nutrition Examination Surveys.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900595-5

Distribution of lipids in 8,500 men with coronary artery disease. Department of Veterans Affairs HDL Intervention Trial Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900595-5

Cholesterol in patients with coronary heart disease: how low should we go?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900595-5

Cholesterol reduction in cardiovascular disease. Clinical benefits and possible mechanisms.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900595-5

The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900595-5

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900595-5

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900595-5

Total cholesterol and risk of mortality in the oldest old.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900595-5

Treating elevated cholesterol levels: the great Satan in perspective

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900595-5

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900595-5

The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900595-5

Rationale and design of a secondary prevention trial of increasing serum high-density lipoprotein cholesterol and reducing triglycerides in patients with clinically manifest atherosclerotic heart disease (the Bezafibrate Infarction Prevention Trial)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900595-5

Plasma fibrinogen levels and their correlates in 6457 coronary heart disease patients. The Bezafibrate Infarction Prevention (BIP) Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900595-5

Rationale and design of the Department of Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial (HIT) for secondary prevention of coronary artery disease in men with low high-density lipoprotein cholesterol and desirable low-densi

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900595-5

Design & rationale of the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900595-5

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900595-5

Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS])

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900595-5

Prognostic significance of progression of coronary atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900595-5

Benefits of lipid-lowering therapy in men with elevated apolipoprotein B are not confined to those with very high low density lipoprotein cholesterol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900595-5

Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900595-5

High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900595-5

The Tromsø heart-study. High-density lipoprotein and coronary heart-disease: a prospective case-control study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900595-5

Design of the Women’s Health Initiative Clinical Trial and Observational Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900595-5

Protocol for a prospective collaborative overview of all current and planned randomized trials of cholesterol treatment regimens. Cholesterol Treatment Trialists' (CTT) Collaboration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900595-5

Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900595-5

Statin trials and goals of cholesterol-lowering therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900595-5

Plasma lipids and diabetes mellitus in an adult community

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900595-5

7 January 2021

Diabetic dyslipidemia

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900595-5

Prior to use of estrogen replacement therapy, are users healthier than nonusers?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900595-5

Myocardial infarction and the use of estrogen and estrogen-progestogen in postmenopausal women.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900595-5

LDL-Apheresis Atherosclerosis Regression Study (LAARS). Effect of aggressive versus conventional lipid lowering treatment on coronary atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900595-5

Low density lipoprotein apheresis improves regional myocardial perfusion in patients with hypercholesterolemia and extensive coronary artery disease. LDL-Apheresis Atherosclerosis Regression Study (LAARS).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900595-5

The effect of LDL apheresis on progression of coronary artery disease in patients with familial hypercholesterolemia. Results of a multicenter LDL apheresis study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900595-5

10.1016/S0002-9149(98)00595-5

7 January 2021

Identifiers

DOI

1 reference

24 September 2017

1 reference